Role of invariant natural killer T cells in immune regulation and as potential therapeutic targets in autoimmune disease

Expert Review of Clinical Immunology

Volumn 2, Issue 5, 2006, Pages 745-757

  Van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

galactosylceramide; Autoimmunity; CD1d; Glyolipids; Immune deviation; Immunotherapy; Invariant natural killer; T cells Tregs

Indexed keywords

EID: 77649084403     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2.5.745     Document Type: Review

References (108)

1. Nossal GJ. Negative selection of lymphocytes. Cell 76(2), 229-239 (1994). (Pubitemid 24046686)
2. von Boehmer H. Positive selection of lymphocytes. Cell 76(2), 219-228 (1994). (Pubitemid 24046685)
3. Miller JF, Basten A. Mechanisms of tolerance to self. Curr. Opin. Immunol. 8(6), 815-821 (1996). (Pubitemid 27007647)
4. Jiang H, Chess L. Regulation of immune responses by T cells. N. Engl J. Med 354(11), 1166-1176(2006).
5. -, in immunological tolerance to self and non-self. Nat. Immunol 6(4), 345-352 (2005). (Pubitemid 41716771)
6. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol 6(4), 331-337 (2005). (Pubitemid 41716769)
7. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol Immunopathol. 84(3), 223-243 (1997). (Pubitemid 27398022)
8. Marrack P, Kappler J, Korzin BL. Autoimmune disease: why and where it occurs. Nat. Med. 7(8), 899-905 (2001). (Pubitemid 32756426)
9. Davidson A, Diamond B. Autoimmune diseases. N. Engl. J. Med. 345(5), 340-350(2001).
10. Becker KG, Simon RM, Bailey-Wilson JF et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc. Natl Acad. Sci. USA 95(10), 9979-9984(1998). (Pubitemid 28415280)
11. McDevitt HO. Discovering the role of the major histocompatibility complex in the immune response. Ann. Rev. Immunol. 18, 1-17 (2000). (Pubitemid 30365372)
12. Villasenor J, Benoist C, Mathis D. AIRE and APECED: molecular insights into an autoimmune disease. Immunol. Rev. 204(1), 156-164(2005). (Pubitemid 40460500)
13. Wildin RS, Freitas A. 1PEX and FOXP3: clinical and research perspectives. J. Autoimmun. 25(Suppl. 1), 56-62 (2005). (Pubitemid 41728046)
14. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347(12), 911-920(2002).
15. Carapetis JR, McDonald M, Wilson MJ. Acute rheumatic fever. Lancet 366(9480), 155-168(2005). (Pubitemid 40991218)
16. Nepom GT. Therapy of autoimmune diseases: clinical trials and new biologies. Curr. Opin. Immunol. 14(6), 812-815 (2002). (Pubitemid 35292431)
17. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 435(7042), 612-619 (2005). (Pubitemid 40825501)
18. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-α agents. Ann. NY Acad Sci. 1051, 559-569 (2005).
19. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Val4 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21, 483-513 (2003). (Pubitemid 37174539)
20. Van Kaer L. Regulation of immune responses by CD Id-restricted natural killer T cells. Immunol. Res. 30(2), 139-153 (2004). (Pubitemid 39425338)
21. Godfrey Dl, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest 114(10), 1379-1388(2004). (Pubitemid 40385565)
22. Brigl M, Brenner MB. CD 1: antigen presentation and T cell function. Ann. Rev. Immunol 22, 817-890 (2004).
23. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Ann. Rev. Immunol. 26, 877-900 (2005). (Pubitemid 40563188)
24. Joyce S, Van Kaer L. CD 1-restricted antigen presentation: an oily matter. Curr. Opin. Immunol. 15(1), 95-104 (2003). (Pubitemid 35454199)
25. De la Salle H, Mariotti S, Angenieux C et al. Assistance of microbial glycolipid antigen processing by CDle. Science 310(5752), 1321-1324 (2005). (Pubitemid 41698862)
26. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat. Rev. Immunol 4(3), 231-237 (2004). (Pubitemid 38339089)
27. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 16(4), 583-594 (2002). (Pubitemid 34442582)
28. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD ld-reactive T cell population reactive to sulfatide. J. Exp. Med. 199(7), 947-957 (2004). (Pubitemid 38481086)
29. Berzins SP, Smyth MJ, Godfrey DI. Working with NKT cells-pitfalls and practicalities. Curr. Opin. Immunol. 17(4), 448-454 (2005).
30. Van Kaer L. α-galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol 5(1), 3142 (2005).
31. Hammond KJ, Kronenberg M. Natural killer T cells: natural or unnatural regulators of autoimmunity? Curr. Opin. Immunol. 15(6), 683-689 (2003). (Pubitemid 37434076)
32. Linsen L, Somers V, Stinissen P. Immunoregulation of autoimmunity by natural killer T cells. Hum. Immunol 66(12), 1193-1202(2005).
33. Van Kaer L, Joyce S. Innate immunity: NKT cells in the spotlight. Curr. Biol. 15(11), R429-R431 (2005). (Pubitemid 40772144)
34. Brutkiewicz RR CD1d ligands: The good, the bad, and the ugly, J. Immunol 177(2), 769-775 (2006).
35. Zhou D, Mattner J, CantuC et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306(5702), 1786-1789 (2004). (Pubitemid 39601398)
36. Gumperz JE, Roy C, Makowska A et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12(2), 211-221(2000). (Pubitemid 30398635)
37. Agea E, Russano A, Bistoni O et al. Human CD1-restricted T cell recognition of lipids from pollens. J. Exp. Med. 202(2), 295-308 (2005). (Pubitemid 41043825)
38. Park J-J, Kang SJ, De Silva AD et al Lipidprotein interactions: biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved. Proc. Natl Acad. Sci. USA 101(4), 1022-1026 (2004). (Pubitemid 38160577)
39. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med 198(1), 173-181 (2003). (Pubitemid 36870197)
40. + T cell lymphoma by natural killer T (NKT) cells. Proc. Natl Acad Sci. USA 99(12), 8197-8202 (2002). (Pubitemid 34651029)
41. Fischer K, Scotet E, Niemeyer M et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc. Natl Acad. Sci. USA 101(29), 10685-10690 (2004). (Pubitemid 38955803)
42. Amprey JL, Im JS, Turco SJ et al. A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J. Exp. Med. 200(7), 895-904 (2004). (Pubitemid 39362925)
43. Mattner J, DeBord KL, Ismail N et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434(7032), 525-529 (2005). (Pubitemid 40477062)
44. Kinjo Y, Wu DY, Kim G et al Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434(7032), 520-525 (2005). (Pubitemid 40477061)
45. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD Id-specific ligand for NKT cells. Eur. J. Immunol 35(6), 1692-1701 (2005). (Pubitemid 40862317)
46. Kawano T, Cui J, Koezuka Y et al CD1d-restricted and TCR-mediated activation of Vol 4 NKT cells by glycosylceramides. Science 278(5343), 1626-1629 (1997). (Pubitemid 27516282)
47. Natori T, Koezuka Y, Higa T. Agelasphins, novel α- galactosylceramides from the marine sponge Agelas mauritianus. Tetrahedron Lett. 34(35), 5591-5592 (1993).
48. Eberl G, MacDonald HR. Rapid death and regeneration of NKT cells in anti-CD3ε-or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 9(3), 345-353 (1998). (Pubitemid 28462755)
49. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol 30(4), 985-992 (2000). (Pubitemid 30216213)
50. Wilson MT, Johansson C, Olivares-Villagomez D et al The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl Acad. Sci. USA 100(19), 10913-10918 (2003). (Pubitemid 37140127)
51. Crowe NY, Uldrich AP, Kyparissoudis K et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells, J. Immunol 171(8), 4020-4027 (2003). (Pubitemid 37238677)
52. Harada M, Seino KI, Wakao H et al. Down-regulation of the invariant Vα 14 antigen receptor in NKT cells upon activation. Int. Immunol 16(2), 241-247 (2004). (Pubitemid 38195654)
53. Parekh W, Wilson MT, Van Kaer L. iNKT-cell responses to glycolipids. Crit. Rev. Immunol 25(3), 183-213 (2005). (Pubitemid 41444904)
54. Van Kaer L. Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol. Cell Biol. 82(3), 315-322 (2004). (Pubitemid 38870026)
55. Bezbradica JS, Stanic AK, Matsuki N et al. Distinct roles of dendritic cells and B cell in Va14Ja18 natural T cell activation in vivo. J. Immunol 174(8), 4694-4705 (2005).
56. Schmieg J, Yang G, Franck RW, Van Rooijen N, Tsuji M. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc. Natl Acad. Sci. USA 102(4), 1127-1132 (2005). (Pubitemid 40170737)
57. Singh N, Hong S, Scheret DC et al. Cutting edge: activation of NK T cells by CD 1 d and a-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol 163(5), 2373-2377 (1999). (Pubitemid 29399153)
58. Burdin N, Brossay L, Kronenberg M. Immunization with a-galactosylceramide polarizes CDl-reactive NK T cells towards Th2 cytokine synthesis. Eur. J. Immunol 29(6), 2014-2025 (1999). (Pubitemid 29265558)
59. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat. Immunol. 3(9), 867-874 (2002).
60. Parekh VV, Wilson MT, Olivares-Villagomez D et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice, J. Clin. Invest. 115(9), 2572-2583 (2005). (Pubitemid 41266220)
61. Ulrich AP, Crowe NY, Kyparissoudis K et al. NKT cell stimulation with glycolipid antigen in vivo; costimulation-dependent expansion, bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175(5), 3092-3101 (2005). (Pubitemid 41170529)
62. Sullivan BA, Kronenberg M. Activation or anergy: NKT cells are stunned by a-galactosylceramide. J. Clin. Invest. 115(9), 2328-2329(2005). (Pubitemid 41266194)
63. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413(6855), 531-534(2001). (Pubitemid 32938752)
64. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198(11), 1631-1641 (2003). (Pubitemid 37494156)
65. Parekh W, Singh AK, Wilson MT et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J. Immunol. 173(6), 3693-3706 (2004). (Pubitemid 39280730)
66. Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EWJ, Murphy WJ, Wiltrout RH. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 172(2), 943-953 (2004). (Pubitemid 38113753)
67. Goff RD, Gao Y, Mattner J et al. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J. Am. Chem. Soc. 126(42), 13602-13603 (2004). (Pubitemid 39407224)
68. Yu KO, Im JS, Molano A et al. Modulation of CD Id-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc. Natl Acad. Sci. USA 102(9), 3383-3388 (2005). (Pubitemid 40328054)
69. Giaccone G, Punt CJA, Ando Y et al. A phase I study of natural killer T-cell ligand a-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer. Res. 8(12), 3702-3709 (2002). (Pubitemid 35424759)
70. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103(2), 383-389 (2004). (Pubitemid 38140063)
71. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195(5), 625-636 (2002). (Pubitemid 34461507)
72. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages oi human Vα24 natural killer T cells. J. Exp. Med. 195(5), 637-641 (2002). (Pubitemid 34461508)
73. Cui J, Watanabe N, Kawano T et al. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells. J. Exp. Med. 190(6), 783-792 (1999). (Pubitemid 29451624)
74. Matsuda JL, Gapin L, Baron JL et al. Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo. Proc. Natl Acad. Sci. USA 100(14), 8395-8400 (2003). (Pubitemid 36842556)
75. Naumov YN, Bahjat KS, Gausling R et al. Activation of CD Id-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl Acad. Sci. USA 98(24), 13838-13843 (2001). (Pubitemid 33115985)
76. Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol 3(3), 211-222 (2003). (Pubitemid 37323206)
77. Kojo S, Seino KI, Harada M et al. Induction of regulatory properties in dendritic cells by Val4 NKT cells. J. Immunol 175(6), 3648-3655 (2005). (Pubitemid 41292024)
78. regs in the prevention of autoimmune myasthenia. J. Immunol 175(12), 7898-7904 (2005). (Pubitemid 41798350)
79. Wilson MT, Singh AK, Van Kaer L. Immunotherapy with ligands of natural killer T cells. Trends Mol. Med. 8(5), 225-231 (2002). (Pubitemid 34493640)
80. Hong S, Wilson MT, Serizawa I et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med 7(9), 1052-1056 (2001). (Pubitemid 32937387)
81. Sharif S, Arreaza GA, Zucker P et al. Activation of natural killer T cells by a-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. 7(9), 1057-1062 (2001). (Pubitemid 32937388)
82. Wang B, Geng YB, Wang CR. CD 1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med 194(3), 313-320 (2001).
83. Mizuno M, Masumura M, Tomi C et al. Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J. Autoimmun. 23(4), 293-300 (2004). (Pubitemid 39574804)
84. Mi QS, Ly D, Zucker P, McGarry M, Delovitch TL. Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T cells. Diabetes 53(5), 1303-1310 (2004). (Pubitemid 38569017)
85. Chen YG, Choisy-Rossi CM, Holl TM et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J. Immunol. 174(3), 1196-1204(2005).
86. Singh AK, Wilson MT, Hong S et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194(12), 1801-1811 (2001). (Pubitemid 34028659)
87. Jahng AW, Maricic I, Pedersen B et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194(12), 1789-1799 (2001). (Pubitemid 34028658)
88. Furlan R, Bergami A, Cantarella D et al. Activation of invariant NKT cells by a-GalCer administration protects mice from MOG35-55 induced EAE: critical roles for administration route and IFN-y. Eur. J. Immunol. 33(7), 1830-1838 (2003). (Pubitemid 37120854)
89. Singh AK, Yang JQ, Parekh W et al. The natural killer T cell ligand a-galactosylceramide prevents or promotes pristane-induced lupus in mice, Eur. J. Immunol. 35(4), 1143-1154 (2005). (Pubitemid 40542221)
90. + T cells for IL-4 production. J. Exp. Med. 199(12), 1619-1630 (2004). (Pubitemid 38821995)
91. Furlan R, Brambilla E, Ruffini F et al. Intrathecal delivery of IFN-y protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol. 167(3), 1821-1829(2001). (Pubitemid 32703187)
92. Chiba A, Old S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of a-galactosylceramide. Arthritis Rheum. 50(1), 305-313(2004). (Pubitemid 38084316)
93. regs and NKT cells: regulators regulating regulators. Trends Immunol 27(7), 322-327 (2006).
94. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B. Schistosoma mansoni and a-galactosylceramide: prophylactic effect of Th1 immune suppression in a mouse model of Graves' hyperthyroidism. J. Immunol. 173(3), 2167-2173 (2004). (Pubitemid 38971656)
95. Yang JQ, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR. Repeated a-galactosylceramide administration results in expansion of Vα 14 NKT cells and alleviates inflammatory dermatitis in MRL-lprllpr mice. J. Immunol. 171(8), 4439-4446 (2003). (Pubitemid 37238724)
96. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Thl-type immune responses exacerbating lupus. J. Clin. Invest. 112(8), 1211-1222 (2003). (Pubitemid 38056298)
97. Major AS, Singh RR, Joyce S, Van Kaer L. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol. Res. 34(1), 49-66 (2006). (Pubitemid 43780376)
98. Mars LT, Novak J, Liblau RS, Lehuen A. Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks. Trends Immunol 25(9), 471-476 (2004). (Pubitemid 39490253)
99. Pearson CI, McDevitt HO. Redirecting Thl and Th2 responses in autoimmune disease. Curr. Top. Microbiol. Immunol 238, 79-122 (1999). (Pubitemid 29012972)
100. Serreze DV, Chapman HD, Post CM, Johnson EA, Suarez-Pinzon WL, Rabinovitch A. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J. Immunol 166(2), 1352-1359 (2001). (Pubitemid 32060298)
101. Osman Y, Kawamura T, Naito T et al Activation of hepatic NKT cells and subsequent liver injury following administration of a-galactosylceramide. Eur. J. Immunol 30(7), 1919-1928 (2000). (Pubitemid 30456188)
102. Ito K, Karasawa M, Kawano T et al Involvement of decidual Va 14 NKT cells in abortion. Proc. Natl Acad. Sci. USA 97(2), 740-744 (2000). (Pubitemid 30070379)
103. Tupin E, Nicoletti A, Elhage R et al. CD Id-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199(3), 417-422 (2004). (Pubitemid 38252053)
104. Nakai Y, Iwabuchi K, Fujii S et al Natural killer T cells accelerate atherogenesis in mice. Blood 104(7), 2051-2059 (2004). (Pubitemid 39297856)
105. Major AS, Wilson MT, McCaleb JL et al Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vase. Biol 24(12), 2351-2357(2004). (Pubitemid 39658041)
106. Major AS, Van Kaer L. The role of natural killer T cells in atherosclerosis. Curr. Immunol Rev. 1(3), 261-274 (2005).
107. Bilenki L, Yang J, Fan Y, Wang S, Yang X. Natural killer T cells contribute to airway eosinophilic inflammation induced by ragweed through enhanced IL-4 and eotaxin production. Eur. J. Immunol. 34(2), 345-354 (2004). (Pubitemid 39255945)
108. Pal E, Tabira T, Kawano T, Taniguchi M, Miyake S, Yamamura T. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα 14 NK T cells. J. Immunol 166(1), 662-668 (2001). (Pubitemid 32038491)